The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis
Open accessAbstract
Background and aims: Immunosuppressive therapy with intravenous ciclosporin is an alternative treatment option to total colectomy for patients with ulcerative colitis (UC), while the benefits of oral administration of tacrolimus are not well defined and are based on reports of several uncontrolled studies. Methods: Patients with refractory active UC were randomly assigned to a high trough concentration (10–15 ng/ml) group (HT group) (n = 21), low trough concentration (5–10 ng/ml) group (LT group) (n = 22), or placebo group (n = 20). Patients received an initial oral dose of 0.05 mg/kg tacrolimus or placebo twice daily. Efficacy was evaluated in 60 patients based on a disease activity index (DAI) score. Fifty eight patients had additional treatment with tacrolimus and were evaluated for efficacy in a 10 week open label extension. Results: An improvement in DAI score (⩾4 points, all categories improved) was observed for 68.4% of cases in the HT group compared with 10.0% in the placebo group (p<0.001). In the HT group, 20.0% of patients had clinical remission and 78.9% had mucosal healing. In the open label extension, 55.2% of all patients had an improved DAI score at week 10. Mean dose of prednisolone was reduced from 19.7 mg/day at study entry to 7.8 mg/day at week 10. The incidence of side effects in the HT group was significantly higher than that of the placebo group (p = 0.043). The most common event was mild finger tremor. Conclusions: Our findings demonstrate dose dependent efficacy and safety of oral tacrolimus for remission-induction therapy of refractory UC. The optimal target range appears to be 10–15 ng/ml in terms of efficacy with two week therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902
Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis
Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712243172603 · Cited by 3,026
Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy
Lichtiger, S., Present, D. H., Kornbluth, A., Gelernt, I., Bauer, J., Galler, G., Michelassi, F., & Hanauer, S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406303302601 · Cited by 1,714
KINO, T., HATANAKA, H., HASHIMOTO, M., NISHIYAMA, M., GOTO, T., OKUHARA, M., KOHSAKA, M., AOKI, H., & IMANAKA, H. (1987) · The Journal of Antibiotics · doi:10.7164/antibiotics.40.1249 · Cited by 1,241
KINO, T., HATANAKA, H., MIYATA, S., INAMURA, N., NISHIYAMA, M., YAJIMA, T., GOTO, T., OKUHARA, M., KOHSAKA, M., AOKI, H., et al. (1987) · The Journal of Antibiotics · doi:10.7164/antibiotics.40.1256 · Cited by 1,209
Järnerot, G., Hertervig, E., Friis-Liby, I., Blomquist, L., Karlén, P., Grännö, C., Vilien, M., Ström, M., Danielsson, Å., Verbaan, H., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.003 · Cited by 1,089
Sutherland, L. R., Martin, F., Greer, S., Robinson, M., Greenberger, N., Saibil, F., Martin, T., Sparr, J., Prokipchuk, E., & Borgen, L. (1987) · Gastroenterology · doi:10.1016/0016-5085(87)90621-4 · Cited by 677
Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study
Sands, B. E., Tremaine, W. J., Sandborn, W. J., Rutgeerts, P. J., Hanauer, S. B., Mayer, L., Targan, S. R., & Podolsky, D. K. (2001) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200105000-00001 · Cited by 422
Probert, C. S. J., Hearing, S. D., Schreiber, S., Kühbacher, T., Ghosh, S., Arnott, I. D. R., & Forbes, A. (2003) · Gut · doi:10.1136/gut.52.7.998 · Cited by 355
Sandborn, W. J., Present, D. H., Isaacs, K. L., Wolf, D. C., Greenberg, E., Hanauer, S. B., Feagan, B. G., Mayer, L., Johnson, T., Galanko, J., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00877-1 · Cited by 333
Ning, Q., Brown, D., Parodo, J., Cattral, M., Gorczynski, R., Cole, E., Fung, L., Ding, J. W., Liu, M. F., Rotstein, O., et al. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.7.3487 · Cited by 303
Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation
Trompeter, R., Filler, G., Webb, N. J. A., Watson, A. R., Milford, D. V., Tyden, G., Grenda, R., Janda, J., Hughes, D., Ehrich, J. H. H., et al. (2002) · Pediatric Nephrology · doi:10.1007/s00467-001-0795-9 · Cited by 227
Fellermann, K. (1998) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(98)00420-1 · Cited by 183
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
(2006) · New England Journal of Medicine · doi:10.1056/nejmx060025 · Cited by 183
Tacrolimus: a new immunosuppressive agent
Kelly, P. A., Burckart, G. J., & Venkataramanan, R. (1995) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/52.14.1521 · Cited by 163
Response of Refractory Colitis to Intravenous or Oral Tacrolimus (FK506)
Fellermann, K., Tanko, Z., Herrlinger, K. R., Witthoeft, T., Homann, N., Bruening, A., Ludwig, D., & Stange, E. F. (2002) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200209000-00002 · Cited by 160
Lowry, P. W., Weaver, A. L., Tremaine, W. J., et al. (1999) · Inflammatory Bowel Diseases · doi:10.1097/00054725-199911000-00001 · Cited by 142
Baumgart, D. C., Wiedenmann, B., & Dignass, A. U. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01534.x · Cited by 133
Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study
Ochsenkühn, T., Sackmann, M. F., & Göke, B. (2004) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200411000-00014 · Cited by 124
Wj, S. (1997) · PubMed · Cited by 123
Wide Variation in Lymphocyte Steroid Sensitivity Among Healthy Human Volunteers
Hearing, S. D., Norman, M., Smyth, C., Foy, C. J. W., & Dayan, C. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.11.6156 · Cited by 115
Effect of oral tacrolimus (FK 506) on steroid‐refractory moderate/severe ulcerative colitis
Högenauer, C., Wenzl, H., Hinterleitner, T. A., & Petritsch, W. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01662.x · Cited by 110
Wide Variation in Lymphocyte Steroid Sensitivity Among Healthy Human Volunteers
Hearing, S. D. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.11.4149 · Cited by 81
Sandborn, W. J. (1997) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-199710000-00027 · Cited by 65
Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis
Sprenger, R., Sagmeister, M., & Offner, F. A. (2005) · Gut · doi:10.1136/gut.2004.049940 · Cited by 56
Lowry, P. W., Weaver, A. L., Tremaine, W. J., et al. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.3780050402 · Cited by 52
Ulcerative colitis associated with interferon treatment for chronic hepatitis C
Mavrogiannis, C. C., Papanikolaou, I. S., Elefsiniotis, I. S., Psilopoulos, D., Karameris, A., & Karvountzis, G. G. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00022-8 · Cited by 51
Oral Tacrolimus (FK 506) in Crohn's Disease Complicated by Fistulae of the Perineum
Ierardi, E., Principi, M., Rendina, M. G., et al. (2000) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200003000-00015 · Cited by 48
Cited by
Kornbluth, A., & Sachar, D. B. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.727 · Cited by 2,023
Inflammatory bowel disease: clinical aspects and established and evolving therapies
Baumgart, D. C., & Sandborn, W. J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60751-x · Cited by 1,920
ACG Clinical Guideline: Ulcerative Colitis in Adults
Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Sauer, B. G., & Long, M. D. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000152 · Cited by 1,577
Dignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M., D'Haens, G., D'Hoore, A., Mantzaris, G., Novacek, G., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.002 · Cited by 1,548
Guidelines for the management of inflammatory bowel disease in adults
Mowat, C., Cole, A., Windsor, A., Ahmad, T., Arnott, I., Driscoll, R., Mitton, S., Orchard, T., Rutter, M., Younge, L., et al. (2011) · Gut · doi:10.1136/gut.2010.224154 · Cited by 1,419
Metadata
- Authors
- Ogata, H., Matsui, T., Nakamura, M., Iida, M., Takazoe, M., Suzuki, Y., & Hibi, T.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2006-02-16
- Volume
- 55
- Issue
- 9
- Pages
- 1255-1262
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2102804688
- Cited by
- 462
- References
- 28
- FWCI
- 13.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.